[go: up one dir, main page]

SI2812351T1 - Farmacevtski sestavek za zdravljenje multiple skleroze - Google Patents

Farmacevtski sestavek za zdravljenje multiple skleroze

Info

Publication number
SI2812351T1
SI2812351T1 SI201331085T SI201331085T SI2812351T1 SI 2812351 T1 SI2812351 T1 SI 2812351T1 SI 201331085 T SI201331085 T SI 201331085T SI 201331085 T SI201331085 T SI 201331085T SI 2812351 T1 SI2812351 T1 SI 2812351T1
Authority
SI
Slovenia
Prior art keywords
treatment
pharmaceutical composition
multiple sclerosis
sclerosis
pharmaceutical
Prior art date
Application number
SI201331085T
Other languages
English (en)
Inventor
Selmaj
Szczepanik
Original Assignee
SELMAJ,Kzysztof
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SELMAJ,Kzysztof filed Critical SELMAJ,Kzysztof
Publication of SI2812351T1 publication Critical patent/SI2812351T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201331085T 2012-02-10 2013-02-08 Farmacevtski sestavek za zdravljenje multiple skleroze SI2812351T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL398077A PL398077A1 (pl) 2012-02-10 2012-02-10 Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego
EP13710308.1A EP2812351B1 (en) 2012-02-10 2013-02-08 Pharmaceutical composition for the treatment of multiple sclerosis
PCT/EP2013/052615 WO2013117742A2 (en) 2012-02-10 2013-02-08 Pharmaceutical composition for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
SI2812351T1 true SI2812351T1 (sl) 2018-11-30

Family

ID=46762685

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331085T SI2812351T1 (sl) 2012-02-10 2013-02-08 Farmacevtski sestavek za zdravljenje multiple skleroze

Country Status (9)

Country Link
US (2) US20150080313A1 (sl)
EP (1) EP2812351B1 (sl)
DK (1) DK2812351T3 (sl)
ES (1) ES2684725T3 (sl)
HU (1) HUE039044T2 (sl)
PL (2) PL398077A1 (sl)
PT (1) PT2812351T (sl)
SI (1) SI2812351T1 (sl)
WO (1) WO2013117742A2 (sl)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2016414E (pt) * 2006-05-05 2015-11-24 Opexa Therapeutics Vacina de células t
EP2240200B1 (en) * 2008-01-25 2016-05-04 Vianex S.A. Therapeutic mannan linked mylein basic protein peptide mbp83-99

Also Published As

Publication number Publication date
EP2812351A2 (en) 2014-12-17
US20150080313A1 (en) 2015-03-19
EP2812351B1 (en) 2018-03-28
ES2684725T3 (es) 2018-10-04
PL2812351T3 (pl) 2018-09-28
US20190201484A1 (en) 2019-07-04
PT2812351T (pt) 2018-08-01
WO2013117742A2 (en) 2013-08-15
WO2013117742A3 (en) 2014-02-20
DK2812351T3 (en) 2018-07-09
HUE039044T2 (hu) 2018-12-28
PL398077A1 (pl) 2012-08-27

Similar Documents

Publication Publication Date Title
PL3378862T3 (pl) Dihydropirymidynoizochinolinony i ich kompozycie farmaceutyczne do leczenia stwardnienia rozsianego
ZA201407726B (en) Pharmaceutical compositions for combination therapy
SG11201503365YA (en) Pharmaceutical compositions for the treatment of cftr mediated diseases
ZA201505443B (en) Compositions containing phorbol esters for the treatment of stroke
SI2814473T1 (sl) Farmacevtske sestave za kombinirano terapijo
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
HUE037176T2 (hu) Olaj-alapú gyógyszerészeti készítmény gasztrointesztinális betegségek kezelésére
SI2812351T1 (sl) Farmacevtski sestavek za zdravljenje multiple skleroze
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
GB201207476D0 (en) pharmaceutical for the treatment of leishmaniasis
PT2814473T (pt) Composições farmacêuticas para terapia de combinação
AU2011900519A0 (en) Drug compositions for the treatment of insomnia